OCULAR THERAPEUTIX, INC (OCUL)

Every figure this model derived for OCUL, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 16,861,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 601,641,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 644,427,000 AssetsCurrent 2026-06-30
current liabilities 49,174,000 LiabilitiesCurrent 2026-06-30
equity 520,041,000 StockholdersEquity 2026-06-30
interest expense 11,403,000 InterestExpenseNonoperating 2026-06-30
ocf -238,239,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 52,054,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 53,281,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up OCUL on one particular measure came for.

RatioValue
cash operating margin-490.21
current ratio13.11
current ratio reported13.11
deferred revenue growth-75.67
dilution pct18.32
fcf margin-490.07
growth cv1.72
interest cover-27.53
operating margin-603.04
owner earnings margin-592.43
revenue growth-8.14
revenue growth per share-22.36
rule of 40-611.18
sbc pct revenue102.36

What to be careful about

What this model itself distrusts about OCUL's figures. Written by the derivation as it ran, not added afterwards.